TY  - JOUR
T1  - MOdeling cardiovascular disease prevention
AU  - Pletcher MJ, Tice JA, Pignone M
Y1  - 2010/03/03
N1  - 10.1001/jama.2010.188
JO  - JAMA
SP  - 835
EP  - 835
VL  - 303
IS  - 9
N2  - 
To the Editor: In their Commentary, Drs Hingorani and Psaty1 invoked the prevention paradox (a large proportion of cardiovascular disease [CVD] events occur among the many individuals with average risk factor values) in their discussion of whether to embrace new CVD risk markers as tools for targeting or personalizing statin therapy. They also described another well-known apparent paradox: even risk markers that are strongly associated with the outcome of interest (relative risks of 3 to 5 or even larger) often seem to contribute little in terms of discrimination or reclassification.2

SN  - 0098-7484
M3  - doi: 10.1001/jama.2010.188
UR  - http://dx.doi.org/10.1001/jama.2010.188
ER  -